28
ADRENERGIC ADRENERGIC ANTAGONISTS ANTAGONISTS

ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

Embed Size (px)

Citation preview

Page 1: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

ADRENERGICADRENERGIC ANTAGONISTSANTAGONISTS

Page 2: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective).•Therapeutic uses: Pheochromocytoma•Side effects: Postural hypotension, nasal stuffiness, inhibit ejaculation and reflex tachycardia.

O

CH3

NCl

phenoxybenzamine

Page 3: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: competitive blocking for α1 and α2 receptors.•Therapeutic uses: short term management of pheochromocytoma, to treat impotence.•Side effects: Postural hypotension, reflex tachycardia., nasal congestion,

N

N NH

OH

CH3

phentolamine

Page 4: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: selective α1 antagonist.•Therapeutic uses: Hypertension.

N

N

N

N

O

O

CH3

OCH3

NH2

O

Prazocin (Minipress)

Page 5: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: selective α1 antagonist.•Therapeutic uses: hypertension.

N

N

N

N

O

CH3

OCH3

NH2

OO

O

Doxazocin (Cadura)

Page 6: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: selective α1A antagonist.•Therapeutic uses: BPH

S

O

O

NH2

O

CH3

CH3NH

H

O

OCH3

Tamsulosin(FloMax)

Page 7: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

1. 1. -Adrenoceptors-Adrenoceptors

NotesNotes•G-Protein-coupled receptorsG-Protein-coupled receptors•Activate generation of cyclic AMPActivate generation of cyclic AMP

33-Adrenoceptor-Adrenoceptor •Predominant receptor in fat cellsPredominant receptor in fat cells•Activation results in fat metabolismActivation results in fat metabolism

22-Adrenoceptor -Adrenoceptor •Predominant receptor in bronchial smooth muscle Predominant receptor in bronchial smooth muscle •Activation results in smooth muscle relaxationActivation results in smooth muscle relaxation

11-Adrenoceptor -Adrenoceptor •Predominant receptor in heart musclePredominant receptor in heart muscle•Activation results in cardiac muscle contractionActivation results in cardiac muscle contraction•Antagonists of this receptor are potential cardiovascular drugsAntagonists of this receptor are potential cardiovascular drugs

Page 8: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

2. Natural messengers 2. Natural messengers

Noradrenaline - neurotransmitterNoradrenaline - neurotransmitter

HO

HO

NH2R

OHH

Adrenaline - hormoneAdrenaline - hormone

HO

HO

NHMeR

OHH

NotesNotes•Activate all adrenergic receptorsActivate all adrenergic receptors•No selectivityNo selectivity

Page 9: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

3. Lead compound 3. Lead compound

•Isoprenaline is aIsoprenaline is a-agonist rather than antagonist-agonist rather than antagonist•Shows selectivity for Shows selectivity for -adrenoceptors-adrenoceptors•NN-Isopropyl group is responsible for selectivity-Isopropyl group is responsible for selectivity

HO

HO

HN

H OH

IsoprenalineIsoprenaline

Isopropyl groupIsopropyl group

Page 10: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

4. Converting an agonist to a partial agonist 4. Converting an agonist to a partial agonist

NotesNotes•Phenol groups are not required for antagonist activityPhenol groups are not required for antagonist activity•Add extra binding groups to convert an agonist to an antagonistAdd extra binding groups to convert an agonist to an antagonist•Hydrophobic groups form extra van der Waals interactionsHydrophobic groups form extra van der Waals interactions•Structure binds but produces a different induced fitStructure binds but produces a different induced fit•Act as partial agonists Act as partial agonists

- weakly activate receptors- weakly activate receptors- block natural messenger- block natural messenger

HO

HO

HN

H OH

IsoprenalineIsoprenaline(agonist)(agonist)

Cl

Cl

HN

H OH

DichloroisoprenalineDichloroisoprenaline(partial agonist)(partial agonist)

HN

H OH

PronethalolPronethalol(partial agonist)(partial agonist)

Page 11: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

5. Converting a partial agonist to an antagonist 5. Converting a partial agonist to an antagonist

Notes on propranololNotes on propranolol•Spacer introduced - chain extension strategySpacer introduced - chain extension strategy•Substituent is positioned at a different part of the ring Substituent is positioned at a different part of the ring •Ether group acts as a hydrogen bond acceptor (extension strategy)Ether group acts as a hydrogen bond acceptor (extension strategy)•10-20 times greater antagonist activity10-20 times greater antagonist activity•Used clinically as a racemateUsed clinically as a racemate•SS-Enantiomer is the active enantiomer-Enantiomer is the active enantiomer•Aryloxypropanolamine structureAryloxypropanolamine structure•Activates Activates 11 and and 22 adrenoceptors adrenoceptors

HN

H OH

PronethalolPronethalol(partial agonist)(partial agonist)

HN

X

OHH

2

•Introduce spacer Introduce spacer (chain extension)(chain extension)•Vary substituent positionVary substituent position

O NHOHH1

PropranololPropranolol(antagonist)(antagonist)

EtherEther

SpacerSpacer

O NHOHH1

PropranololPropranolol(antagonist)(antagonist)

Page 12: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

NN-Alkyl-Alkylgroupgroup

7. SAR on aryloxypropanolamines 7. SAR on aryloxypropanolamines

NotesNotes•Ether acts as a hydrogen bond acceptorEther acts as a hydrogen bond acceptor•Ether can be replaced with an alternative HBA (O or NH)Ether can be replaced with an alternative HBA (O or NH)•Alcohol is essential as a hydrogen bonding groupAlcohol is essential as a hydrogen bonding group•Amine is ionised and forms an ionic bond with the binding siteAmine is ionised and forms an ionic bond with the binding site•Amine must be secondaryAmine must be secondary•Naphthalene is replacable with heteroaromatic ringsNaphthalene is replacable with heteroaromatic rings•Branched Branched NN-alkyl group fits a hydrophobic pocket-alkyl group fits a hydrophobic pocket•Extension of Extension of NN-alkyl group with -alkyl group with NN-arylethyl group is beneficial-arylethyl group is beneficial

OH

O NH

EtherEther

AlcoholAlcohol

NaphthaleneNaphthalene

AmineAmine

OH

O NH

OH

O NH

SubstitutionSubstitutionlowers activitylowers activity

Aryloxy groupAryloxy group

OH

O NH

PropanolaminePropanolamine groupgroup

Aryloxy groupAryloxy group

OH

O NH

Page 13: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

8. Variation of the naphthalene ring 8. Variation of the naphthalene ring

PropranololPropranolol

OH

O NH

O NH

NH

OHHO N

H

N S

NN

O OHH

PindololPindolol TimololTimolol

Page 14: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

NotesNotes

•Propranolol acts against both Propranolol acts against both 11 and and 22-adrenoceptors-adrenoceptors

•Cannot be used with asthmatic patientsCannot be used with asthmatic patients

•Antagonism of Antagonism of 22-adrenoceptors constricts airways-adrenoceptors constricts airways

•Second generation Second generation -blockers are designed to be -blockers are designed to be 11 -selective -selective

9. Second generation 9. Second generation -blockers -blockers

Page 15: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

9. Second generation 9. Second generation -blockers -blockers

O NH

NHCOCH3

OHH

NotesNotes•Selective cardiac Selective cardiac 11-antagonist-antagonist•More polar More polar •Less CNS side effectsLess CNS side effects•First cardioselective First cardioselective 11-blocker used for the treatment of angina and -blocker used for the treatment of angina and

hypertensionhypertension•Withdrawn due to serious side effects in some patientsWithdrawn due to serious side effects in some patients

PractololPractolol

Page 16: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

Practolol - binding interactionsPractolol - binding interactions•Amido group must be Amido group must be parapara for for 11-selectivity-selectivity•Extra hydrogen bonding interaction takes placeExtra hydrogen bonding interaction takes place•Not possible with Not possible with 22-adrenoceptor-adrenoceptor

9. Second generation 9. Second generation -blockers -blockers

para substitutionExtra H-bonding interaction

meta substitution

HN CH3

O

XH

OH

O NH2

NH

H3C

O

XH

OH

O NH2

Page 17: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

Other agentsOther agents

9. Second generation 9. Second generation -blockers -blockers

OH

O NH

NHCOnPr

O

OH

O NH

CH2CONH2

OH

O NH

CH2CH2OMe

OH

O NH

CH2CH2OCH2

AcebutololAcebutolol AtenololAtenolol MetoprololMetoprolol BetaxololBetaxolol

Page 18: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

NotesNotes•Includes an Includes an NN-arylalkyl group -arylalkyl group •Additional hydrogen bonding interactions are possibleAdditional hydrogen bonding interactions are possible•Extension strategyExtension strategy

10. Third generation 10. Third generation -blockers -blockers

EpanololEpanolol

NC

O

OH

NH

HN

O

PrimidololPrimidolol

H3C

O

OH

NH

N

HNO

O

CH3

XamoterolXamoterol OH

O

OH

NH

HN

O

N

O

Extra H-bonding interactionsExtra H-bonding interactions

EpanololEpanolol

NC

O

OH

NH

HN

O

PrimidololPrimidolol

H3C

O

OH

NH

N

HNO

O

CH3

XamoterolXamoterol OH

O

OH

NH

HN

O

N

O

Page 19: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: non selective β Blocker•Therapeutic uses: effect on heart, eye and lungs. Used for migraine, hyperthyroroidism•Side effects: bronchoconstricion, sexual\d impairment, increases sodium retension, masking hypoglycemia, and reduces glycogenlysis

O

NH

OH

CH3CH3

Propranolol(Inderal)

Page 20: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: non selective β Blocker, more potent than propranolol. It has long duration of action•Therapeutic uses:

OH

OH

O

NH

OH

CH3CH3

CH3

Nadolol (Corgard)

Page 21: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: non selective β Blocker, more potent than propranolol.•Therapeutic uses: Txt of chronic open-angle glaucoma. N

O

N

N

S

O

NHCH3

CH3

OH

CH3

Timolol

Page 22: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: Non-selective β blocker. It has intrinsic agonist activity (B3).•Used to trt pts of HTN and HF.

O

NH

OH

CH3CH3

NH

Pindolol

Page 23: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: selective β 1 blocker. It has intrinsic agonist activity. Less disturbance on the fat and CH metabolism.•Therapeutic uses: hypertension . It can be used for HT in diabetics. It cannot be used for arrythemia.•Side effects: coldness of extremities (less common than non selective).

O

NH

CH3

CH3

NH

CH3

OH

CH3

O

O

Acebutolol

Page 24: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: selective β1 blocker.•Cheap and selective O

NH

CH3

OH

CH3

NH2O

Atenolol (Hypoten)

Page 25: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: selective β1 blocker, very short time of action so only for parental use•Structure-based explanation of Therapeutic uses: hypertension

O

NH

CH3

O

OH

CH3

O

CH3

Esmolol

Page 26: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: selective β1 blocker

O

NH

CH3

OH

CH3

O

CH3

Metoprolol(lopresor)

Page 27: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: β+ α1 blocker.•Therapeutic uses: elderly and black people (it has peripheral vasodilatation). It is also alternative of methyldopa in perganant women. It is used for emergency as \well because of its efficacy.•Side effects: orthostatic hypotension.

NH

OH

CH3

NH2

O

OH

Labetalol

Page 28: ADRENERGIC ANTAGONISTS ANTAGONISTS. Mechanism of action: irreversible(covalent bond) inhibition of α1 and α2 receptors (Nonselective). Therapeutic uses:

•Mechanism of action: β+ α1 blocker. It reduces lipid peroxidation so good for heart failure.(Cardioprotective)

NH ONH O

OH

O

CH3

Carvedilol(Dilatrend)